Tirat Carmel, Israel – March 19, 2009 – InSightec Ltd. reported today that it has closed an internal round of financing totaling $15 million from its existing investors.
Elbit Imaging Ltd. (NASDAQ: EMITF) (“EI”) has invested $7.5M on March 18, 2009. Additional $7.5M would be invested no later than 12 months following the date hereof by its existing investors.
The investment will take the form of Preferred Shares B, which are convertible to InSightec’s ordinary shares subject to the fulfillment of certain conditions stipulated in the agreement.
InSightec reported that the funds would be used to expand its research and development efforts, for marketing and sales activities, and for general corporate purposes.
InSightec’s President and CEO, Dr. Kobi Vortman said ”we are very proud in the ongoing trust we are receiving from our investors that share our vision that this technology is the enabler of the next generation operating room that will be a non-invasive and outpatient operating room.”
“The ExAblate® 2000 treatments of uterine fibroids continue to grow globally with excellent clinical results driving market adoption in more than 70 leading sites globally and over 4500 women treated worldwide. In parallel, InSightec is expanding its research into the oncology areas: bone metastases, prostate cancer, breast cancer, liver tumors and brain tumors. Recent publications have shown that Magnetic Resonance-guided Focused Ultrasound (MRgFUS) with the ExAblate® system has the potential to be an effective noninvasive pain-relieving treatment for tumors that have spread to the bones (bone metastases). InSightec is conducting a phase III pivotal trial for the treatment of pain palliation of bone metastases. In addition, a Fertility Enhancement study is being performed evaluating the potential of ExAblate fibroids’ treatments to enhance fertility when other potential causes of women’s infertility have been ruled out.
The investment will allow acceleration of the technical and clinical research for oncology applications providing improved care for patients around the world.”
About ExAblate® 2000
ExAblate is the first system to use the MR guided focused ultrasound technology that combines MRI – to visualize the body anatomy, plan the treatment and monitor treatment outcome in real time – and high intensity focused ultrasound to thermally ablate tumors inside the body non-invasively. MR thermometry, provided uniquely by the system, allows the physician to control and adjust the treatment in real time to ensure that the targeted tumor is fully treated and surrounding tissue is spared. The ExAblate system was approved by the U.S. Food and Drug Administration in 2004 as a treatment for symptomatic uterine fibroids. Over 4,500 women have been treated world wide to date. ExAblate® 2000 received the European CE Mark certification for pain palliation of bone metastases in June 2007.
InSightec Ltd. is a privately held company owned by Elbit Imaging, GE, MediTech Advisors, LLC and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 160 employees and has invested more than $120 million in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas. For more information, please go to: http://www.insightec.com/